Dr. Reddy's Laboratories Ltd. (RDY)
| Market Cap | 12.26B |
| Revenue (ttm) | 2.32B |
| Net Income (ttm) | 258.59M |
| Shares Out | 165.77M |
| EPS (ttm) | 1.58 |
| PE Ratio | 46.93 |
| Forward PE | 31.15 |
| Dividend | $25.00 |
| Dividend Yield | 33.76% |
| Trading Day | June 11 |
| Last Price | $74.06 |
| Previous Close | $72.61 |
| Change ($) | 1.45 |
| Change (%) | 2.00% |
| Day's Open | 73.00 |
| Day's Range | 72.88 - 74.11 |
| Day's Volume | 168,062 |
| 52-Week Range | 51.12 - 74.11 |
These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on ...
DUBAI, UAE, June 3, 2021 /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being...
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...
The large generics manufacturer's share price is up more than 35% over the past year.
Tired of expensive stocks being just of reach? Look abroad for some great buying opportunities.
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy'...
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) today announced that it has received the permission from the Drug Controller Gen...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy'...
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such...
New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...
Dr. Reddy's Laboratories Ltd (NYSE: RDY) has initiated the process with the Drugs Controller General of India for Emergency Use Authorization (EUA) of the human adenoviral vector-based platform COVID-19...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) today announce...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy'...
HYDERABAD, India and PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Redd...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy'...
Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.
Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2021 Results - Earnings Call Transcript
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and the ni...
Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.
KUWAIT CITY, Jan. 27, 2021 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") and...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) and Global Res...
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of I...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safe...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the third quarter ended December 31, 2020 on Friday, J...
Here we discuss four emerging market stocks, BCAUY, BIDU, IMPUY and RDY, which have solid growth prospects for 2021.
HYDERABAD, India & MISSISSAUGA, Ontario & HALIFAX, Nova Scotia--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY referred to as “Dr. Reddy's”) today announced the secondary listing of its Americ...
3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced adaptive phase...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announc...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announc...
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today annou...
Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Depart...
Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q2 2021 Results - Earnings Call Transcript
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that Parag Agarwal will be joining the Company as Chief Financial Officer (Designa...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended Septe...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announc...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, today announced that th...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, October 28th, ...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, becoming the...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announc...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announc...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.Reddy’s”) today announce...
About RDY
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished ... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1984 |
| CEO G. Prasad | Country India |
| Stock Exchange NYSE | Ticker Symbol RDY |
Financial Performance
In 2019, RDY's revenue was 174.60 billion, an increase of 13.49% compared to the previous year's 153.85 billion. Earnings were 19.50 billion, an increase of 3.74%.
Analyst Forecasts
According to 2 analysts, the average rating for RDY stock is "Buy." The 12-month stock price forecast is 80.78, which is an increase of 9.07% from the latest price.